The modeling of multicancer early detection (MCED) tests' residual risk and the challenges of MCED evaluation and implementation

Larry Kessler¹, Michelle M Le Beau^{2

3}, Robert A Smith⁴, Fiona M Walter^{5

6}, Richard Wender⁷

Affiliations

¹ Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle, Washington, USA.
² Medicine-Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
³ Cancer Prevention & Research Institute of Texas, Austin, Texas, USA.
⁴ Early Cancer Detection Science, American Cancer Society, Atlanta, Georgia, USA.
⁵ Wolfson Institute of Population Health, London, UK.
⁶ Primary Care Cancer Research, Queen Mary University of London, London, UK.
⁷ Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Free article

Editorial

Larry Kessler et al. Cancer. 2023.

Free article

. 2023 Jul 1;129(13):1966-1968.

doi: 10.1002/cncr.34745. Epub 2023 Mar 21.

Larry Kessler¹, Michelle M Le Beau^{2

3}, Robert A Smith⁴, Fiona M Walter^{5

6}, Richard Wender⁷

¹ Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle, Washington, USA.
² Medicine-Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
³ Cancer Prevention & Research Institute of Texas, Austin, Texas, USA.
⁴ Early Cancer Detection Science, American Cancer Society, Atlanta, Georgia, USA.
⁵ Wolfson Institute of Population Health, London, UK.
⁶ Primary Care Cancer Research, Queen Mary University of London, London, UK.
⁷ Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

No abstract available

Comment on

Modeled residual current cancer risk after clinical investigation of a positive multicancer early detection test result.
Hudnut AG, Hubbell E, Venn O, Church TR. Hudnut AG, et al. Cancer. 2023 Jul 1;129(13):2056-2063. doi: 10.1002/cncr.34747. Epub 2023 Mar 21. Cancer. 2023. PMID: 36943898

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi:10.3322/caac.21590
1. Crosby D, Lyons N, Greenwood E, et al.; Early Detection and Diagnosis Roadmap Steering Group. A roadmap for the early detection and diagnosis of cancer. Lancet Oncol. 2020;21(11):1397-1399. doi:10.1016/S1470-2045(20)30593-3
1. Elliss-Brookes L, McPhail S, Ives A, et al. Routes to diagnosis for cancer-determining the patient journey using multiple routine data sets. Br J Cancer. 2012;107(8):1220-1226. doi:10.1038/bjc.2012.408
1. Beer TM. Novel blood-based early cancer detection: diagnostics in development. Am J Manag Care. 2020;26(suppl 14):S292-S299. doi:10.37765/ajmc.2020.88533
1. Hudnut AG, Hubbell E, Venn O, Church TR. Modeled residual current cancer risk after clinical investigation of a positive multicancer early detection test result. Cancer. 2023. doi:10.1002/cncr.34747